Abdul Ameer, E., Abdul Ghafour, K. (2021). Expression of p53 in Pancreatic Ductal Adenocarcinoma. Alustath, 21(2), 255-259. doi: 10.52573/ipmj.2021.174638
Estabraq Ali Abdul Ameer; Kifah Hamdan Abdul Ghafour. "Expression of p53 in Pancreatic Ductal Adenocarcinoma". Alustath, 21, 2, 2021, 255-259. doi: 10.52573/ipmj.2021.174638
Abdul Ameer, E., Abdul Ghafour, K. (2021). 'Expression of p53 in Pancreatic Ductal Adenocarcinoma', Alustath, 21(2), pp. 255-259. doi: 10.52573/ipmj.2021.174638
Abdul Ameer, E., Abdul Ghafour, K. Expression of p53 in Pancreatic Ductal Adenocarcinoma. Alustath, 2021; 21(2): 255-259. doi: 10.52573/ipmj.2021.174638

Expression of p53 in Pancreatic Ductal Adenocarcinoma

Iraqi Postgraduate Medical Journal
Article 19, Volume 21, Issue 2, April 2022, Pages 255-259    PDF (480.96 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2021.174638
Authors
Estabraq Ali Abdul Ameer; Kifah Hamdan Abdul Ghafour
Department of Pathology, College of Medicine/ University of Baghdad., Baghdad, Iraq.
Abstract
BACKGROUND:
Pancreatic adenocarcinoma is one of the major causes of cancer death in the world. Alterations in the p53 tumor suppressor gene stand out as the most common alteration in many cancers including 75% of pancreas cancer. Pancreatic adenocarcinoma in which p53 is mutated carry a poor prognosis, because of late-stage detection, the presence of vascular invasion, metastases, and ineffective treatment options.
OBJECTIVE:
To evaluate the expression of P53 in pancreatic ductal adenocarcinoma immunohistochemically and clinicopathologic correlation with grade and stage.
MATERIALS AND METHODS:
This is a retrospective study of 40 pancreatic biopsies (formalin fixed, paraffin embedded) were collected from archived materials from GIT and Hepatology teaching hospital in Baghdad medical city (from December 2018 to October 2019). Study group include 40 cases of Pancreatic adenocarcinoma, 20 were EUS guided core needle biopsy, and the other 20 were pancreatic tissue from patients sustained whipple surgery.
Two sections of 5μm thickness were taken from each block, the first was stained with H&E,                          the second was stained Immunohistochemical for P53.
RESULTS:
Forty cases are studied and show +ve staining for P53 (100%), 24(60.0%) were males and 16(40.0%) were females, The age of patients ranged from 35 to 70  years with mean ± SD of 56.28±10.2 years. Seventeen were score 4+, thirteen were score 3+, six were score 2+ and four were score 1+.
Tumors with low grade were 20 (50.0%) cases, moderate grade were 15 (37.5%) cases, and high grade were 5 (12.5%) cases.
20 cases were staged from patients underwent whipple surgery.
Tumors with stage T1 N0 Mx were 2(10%), stage T2 N0 Mx were 5(25%), stage T2 N1 Mx were 4(20%), stage T3 N0 Mx were 8(40%), and stage T3 N1 Mx were 1(5%)
CONCLUSION:
There was statistical correlation between P53 expression and tumor grade but not with stage.
 
Keywords
P53 expression; Pancreatic adenocarcinoma
References
  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68:394-424.
  2. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. 2018.
  3. Pourhoseingholi MA, Ashtari S, Hajizadeh N, Fazeli Z, Zali MR. Systematic review of pancreatic cancer epidemiology in Asia-Pacific Region: major patterns in GLOBACON 2012. Gastroenterology and hepatology from bed to bench. 2017;10:245.
  4. Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL, Heinemann V. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15:8-18.
  5. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal.. 2013;6:l1.
  6. Apple SK, Hecht JR, Lewin DN, Jahromi SA, Grody WW, Nieberg RK. Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Human pathology. 1999;30:123-29.
  7. Zhao H, Wang Q, Wang X, Zhu H, Zhang S, Wang W, Wang Z, Huang J. Correlation between RAB27B and p53 expression and overall survival in pancreatic cancer. Pancreas. 2016;45:204.
  8. DiGiuseppe JA, Hruban RH, Goodman SN, Polak M, Van Den Berg FM, Allison DC, Cameron JL, Johan A. Offerhaus G. Overexpression of p53 protein in adenocarcinoma of the pancreas. American journal of clinical pathology. 1994 Jun 1;101:684-88.
  9. Slebos RJ, Hoppin JA, Tolbert PE, Holly EA, Brock JW, Zhang RH, Bracci PM, Foley J, Stockton P, McGregor LM, Flake GP. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiology and Prevention Biomarkers. 2000;9:1223-32.
10. Qureshi A, Hassan U, Azam M. Morphology, TNM staging and survival with pancreatico-duodenectomy specimens received at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Pakistan. Asian Pac J Cancer Prev. 2011;12:953-56.

11. Abdulghafour KH, Khalf SA. CA19-9 and CK immunohistochemical expression in pancreatic and ampulla of vater carcinomas (A clinicopathological study. Journal of the Faculty of Medicine. 2014;56:308-12.

12. Eissa AH. Carcinoma of The Pancreas A Retrospective Study of Pancreatic Cancer of 320 Case from 1976 to 2011. Medical Journal of Babylon. 2014;11:971-83.

13. Jeong J, Park YN, Park JS, Yoon DS, Chi HS, Kim BR. Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei medical journal. 2005 Aug 31;46:519-25.

14. Kim YC, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Shin JH. Can preoperative CA19‐9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?. Journal of gastroenterology and hepatology. 2009 ;24:1869-75.

15. Linder S, Parrado C, Falkmer UG, Blåsjö M, Sundelin P, Von Rosen A. Prognostic significance of Ki-67 antigen and p53 protein expression in pancreatic duct carcinoma: a study of the monoclonal antibodies MIB-1 and DO-7 in formalin-fixed paraffin-embedded tumour material. British journal of cancer. 1997;76:54.

16. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowskal H, Strzelczyk J, Janiak A, Malecka-Panas E. Comparative evaluation of p53 mutation in pancreatic adenocarcinoma and chronic pancreatitis. Hepato-gastroenterology. 2006;53:608-12.

17. Dong M, Dong Q, Zhang H, Zhou J, Tian Y, Dong Y. Expression of Gadd45a and p53 proteins in human pancreatic cancer: potential effects on clinical outcomes. Journal of surgical oncology. 2007;95:332-36.

18. Coppola D, Lu L, Fruehauf JP, Kyshtoobayeva A, Karl RC, Nicosia SV, Yeatman TJ. Analysis of p53, p21WAF1, and TGF-β1 in human ductal adenocarcinoma of the pancreas: TGF-β1 protein expression predicts longer survival. American journal of clinical pathology. 1998;110:16-23.

Statistics
Article View: 62
PDF Download: 41


Journal Management System. Powered by ejournalplus.com